Strategic Global Advisors LLC Sells 70,391 Shares of Bristol-Myers Squibb (NYSE:BMY)

Strategic Global Advisors LLC decreased its holdings in Bristol-Myers Squibb (NYSE:BMYFree Report) by 40.8% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 102,075 shares of the biopharmaceutical company’s stock after selling 70,391 shares during the quarter. Bristol-Myers Squibb makes up about 1.2% of Strategic Global Advisors LLC’s investment portfolio, making the stock its 23rd largest position. Strategic Global Advisors LLC’s holdings in Bristol-Myers Squibb were worth $5,237,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. McClarren Financial Advisors Inc. increased its stake in shares of Bristol-Myers Squibb by 532.7% in the 4th quarter. McClarren Financial Advisors Inc. now owns 1,879 shares of the biopharmaceutical company’s stock valued at $96,000 after buying an additional 1,582 shares during the period. Institute for Wealth Management LLC. increased its stake in shares of Bristol-Myers Squibb by 1.0% in the 4th quarter. Institute for Wealth Management LLC. now owns 30,056 shares of the biopharmaceutical company’s stock valued at $1,542,000 after buying an additional 296 shares during the period. Great Diamond Partners LLC grew its stake in shares of Bristol-Myers Squibb by 9.2% during the fourth quarter. Great Diamond Partners LLC now owns 4,372 shares of the biopharmaceutical company’s stock worth $224,000 after purchasing an additional 367 shares during the period. Principal Securities Inc. acquired a new stake in shares of Bristol-Myers Squibb during the fourth quarter worth $1,139,000. Finally, Scotia Capital Inc. grew its stake in shares of Bristol-Myers Squibb by 48.6% during the fourth quarter. Scotia Capital Inc. now owns 236,724 shares of the biopharmaceutical company’s stock worth $12,146,000 after purchasing an additional 77,471 shares during the period. Institutional investors own 76.41% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on BMY shares. Wells Fargo & Company lifted their price objective on Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a research note on Thursday, April 18th. Barclays decreased their price objective on Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating for the company in a research note on Friday, April 26th. William Blair reaffirmed a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Monday, April 1st. StockNews.com raised Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Thursday, May 23rd. Finally, BMO Capital Markets decreased their target price on Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a research note on Friday, April 26th. One analyst has rated the stock with a sell rating, fifteen have given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $60.00.

Read Our Latest Stock Report on BMY

Bristol-Myers Squibb Stock Up 2.3 %

Shares of Bristol-Myers Squibb stock traded up $0.94 during trading on Monday, reaching $42.42. The stock had a trading volume of 6,610,640 shares, compared to its average volume of 15,433,256. The company has a market capitalization of $85.99 billion, a price-to-earnings ratio of -13.53, a P/E/G ratio of 14.04 and a beta of 0.43. The stock has a fifty day moving average price of $45.50 and a two-hundred day moving average price of $48.98. Bristol-Myers Squibb has a 52 week low of $39.91 and a 52 week high of $66.38. The company has a current ratio of 1.11, a quick ratio of 0.99 and a debt-to-equity ratio of 2.99.

Bristol-Myers Squibb (NYSE:BMYGet Free Report) last released its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.53) by $0.13. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. The business had revenue of $11.87 billion for the quarter, compared to analyst estimates of $11.45 billion. During the same quarter in the prior year, the company posted $2.05 earnings per share. Bristol-Myers Squibb’s revenue was up 4.7% on a year-over-year basis. Sell-side analysts predict that Bristol-Myers Squibb will post 0.59 EPS for the current fiscal year.

About Bristol-Myers Squibb

(Free Report)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Read More

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMYFree Report).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.